Authors: S L Bonnick T J Beck F Cosman M C Hochberg H Wang A E de Papp
Publish Date: 2008/10/02
Volume: 20, Issue: 6, Pages: 911-921
Abstract
DXAbased hip structural analysis from 947 individuals completing two large osteoporosis clinical trials was pooled and analyzed Treatment with onceweekly OW ALN or OW RIS resulted in significant improvements from baseline in geometric parameters at all three HSA ROIs Improvements were generally greater with OW ALN than OW RISBMD can be altered by changes in distribution and quantity of bone and changes in mineralization These effects cannot be distinguished with conventional measurements of BMD Currently tissue composition is evaluated only by invasive means Structural geometry of the proximal femur however can be measured in vivo by several methods including dual energy Xray absorptiometry DXA using specialized hip structure analysis HSA softwareDXAbased HSA was obtained and analyzed in a subset of 947 subjects participating in the Fosamax Actonel Comparison Trials Data were pooled to evaluate treatment effects on the structural geometry of the proximal femur by onceweekly alendronate ALN 70 mg and risedronate RIS 35 mg in postmenopausal women with low bone massBoth ALN and RIS treatment over 2 years resulted in improvements in HSAderived geometry at all three HSA regions of interest ROI The largest treatment effects were seen at the intertrochanteric ROI Consistently greater treatment effects were seen with ALN compared with RIS at all three HSAROIsSydney L Bonnick reports receiving consulting fees from Merck Co Inc Amgen Novartis and Wyeth speaker honoraria from Novartis Wyeth and Merck and research support from Amgen and Takeda Thomas J Beck reports receiving speakers’ fees from Merck Eli Lilly and Amgen and research support from Merck Eli Lilly Aventis NPS Pharmaceuticals and Amgen he also has served on an advisory board for Merck Marc Hochberg serves on advisory boards for and/or receives consulting fees from the following companies that have products for the management of patients with low bone mineral density Amgen Merck Novartis Pharma AG Roche Pharmaceutical Co and Wyeth Pharmaceutical Co Anne de Papp and Hongwei Wang are employees of Merck Co Inc and may own stock or have other equity interests in the company
Keywords: